Siddhartha Devarakonda, MD

Articles by Siddhartha Devarakonda, MD

Second-Line Treatment Decision-Making

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 15th 2026

Following osimertinib monotherapy progression without CNS involvement, clinicians choose between COMPEL (continuing osimertinib plus chemotherapy) and MARIPOSA-2 (amivantamab plus chemotherapy without osimertinib continuation).

Disease Progression Workup and Resistance Testing

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 15th 2026

At disease progression, comprehensive tumor characterization becomes as important as initial diagnosis. Dr. Camidge argues against using regimens that don't require resistance mechanism identification, emphasizing that understanding heterogeneous resistance mechanisms guides optimal therapy selection.

TP53 Mutations in EGFR-Mutant and Risk Stratification

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 8th 2026

TP53 mutations occur in over 50% of patients with EGFR-mutant lung cancer, representing a consistently negative prognostic factor. Dr. Rotow explains that TP53 mutations appear prominently on NGS reports, requiring clinicians to determine appropriate management strategies.

Subcutaneous Amivantamab and Administration Considerations

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 8th 2026

The FDA approval of subcutaneous amivantamab with monthly dosing represents a significant advancement in treatment convenience. Dr. Devarakonda emphasizes that while toxicity concerns shouldn't discourage effective regimen use, practical barriers including time and supportive care requirements make subcutaneous administration valuable.

Patient-Reported Outcomes and Toxicity Assessment

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 1st 2026

Dr. Rotow discusses limitations of traditional CTCAE toxicity grading for capturing patient experiences with EGFR-targeted therapies. Although useful for discrete, measurable, and life-threatening toxicities, CTCAE poorly captures lower-grade effects like skin rash or fatigue that significantly impact quality of life over extended treatment periods.

Comparing Intensification Strategies and Toxicity Profiles

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

July 1st 2026

The panel contrasts FLAURA-2 (osimertinib plus chemotherapy) with MARIPOSA (osimertinib plus amivantamab), acknowledging similar efficacy profiles with overall survival approaching four years in both regimens. However, significant differences exist in toxicity profiles and supportive care requirements.

Shared Decision-Making and Risk Stratification in EGFR-Mutant NSCLC

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

June 24th 2026

Dr. Julia Rotow emphasizes shared decision-making as essential for frontline treatment selection, noting the dramatic shift from osimertinib monotherapy as standard to combination therapy as default over the past 2 to 3 years. Treatment decisions require balancing disease-associated risk factors with patient-specific considerations.

Introduction and Frontline Treatment Options for EGFR-Mutated NSCLC

ByBenjamin P. Levy, MD,D. Ross Camidge, MD, PhD, University of Colorado,Siddhartha Devarakonda, MD,Gilberto Lopes, MD,Julia K. Rotow, MD

June 24th 2026

Dr. Benjamin Levy introduces an expert panel to discuss the increasingly complex landscape of EGFR-mutant advanced non-small cell lung cancer (NSCLC) treatment. The frontline setting now includes three viable options representing a significant shift from the previously straightforward osimertinib monotherapy approach.

Dr. Devarakonda on Biomarkers Beyond PD-L1 in NSCLC

BySiddhartha Devarakonda, MD

May 11th 2017

Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).